ProfessorLuke Bereznicki

Pro Vice-Chancellor Learning and Teaching Performance

Office of Academic Operations

  • Pro Vice-Chancellor Learning and Teaching Performance
    Office of Academic Operations
  • +61 3 6226 2195 (Work)
  • +61 3 6226 2870 (Fax)
  • College Office - College of Health and Medicine, College Office - CHM, 17 Liverpool St, Hobart, TAS, 7001, Australia

RESEARCH SUMMARy

Luke has been a chief investigator on several major national projects that have investigated and implemented new professional activities for Australian health professionals. He has published over 240 peer-reviewed papers, has >380 research outputs and attracted over $13.5 million in competitive funding in the course of his career. He has authored >80 peer-reviewed papers in professional pharmacy journals, focussed on providing health professionals with evidence-based practice review articles on a variety of topics and the fundamentals of evidence-based practice and research principles.

 

Luke co-directed the Unit for Medication Outcomes Research and Education, a research group within the School of Pharmacy and Pharmacology at the University of Tasmania which focusses on improving quality use of medicines from 2015-2021. He has demonstrated a strong commitment to research training and leadership through HDR supervision (18 completions), mentoring of academics and the development of research curricula. Many of Luke’s HDR candidates are now established leaders within academic and clinical practice.

 

Luke has an outstanding national reputation for his contributions within multidisciplinary research and quality improvement teams. He has led several large implementation research projects, with a focus on translation of research evidence into practice. Highlights of this work include the development and implementation of services at a national level, including a national clinical interventions service for pharmacists, post-discharge medication reviews for patients discharged from hospital on anticoagulant medications, partnered medication charting, anticoagulation clinics in rural general practices and pharmacies, and self-monitoring of warfarin therapy in the elderly.

 

Recent highlights include leading the Tasmanian arms of the Commonwealth Department of Health projects focussed on reducing medication-induced deterioration and adverse reactions in aged care facilities with the University of South Australia and improving asthma control in the community pharmacy setting with the University of Sydney. Luke was also the lead investigator on an HCF Research Foundation-funded trial to investigate the effectiveness of post-discharge pharmacist-led intervention to reduce the incidence of adverse drug reactions (2019-2023).

FUNDED PROJECTS

  • GRANT
    Blood clots in Tasmanian cancer patients: what is the risk and how effectively are we preventing them?
    1 Jan 2021 - 31 Dec 2021
    People funded by this grant:
    • Batt T,
    • Mirkazemi C,
    • Peterson G,
    • Bereznicki L
    Project Total: $9,497; Blood clots are a serious and often life-threatening complication of cancer that can be largely avoided with appropriate care. We will review preventative practices used locally, as well as associated influences, with the aim to optimise care and reduce this risk in future Tasmanians diagnosed with cancer. Funded by: Royal Hobart Hospital Research Foundation - Grant-Incubator; University of Tasmania.
  • GRANT
    Adverse drug reaction-related hospital admission in elderly Australians with dementia
    1 Jan 2020 - 30 Jun 2021
    People funded by this grant:
    • Parameswaran Nair N,
    • Bereznicki L,
    • Adamczewski B,
    • Salahudeen M,
    • Bereznicki B
    Project Total: $9,985; Dementia is a significant risk factor for serious side effects of medicines or adverse drug reactions (ADRs). This prospective study will investigate and identify the prevalence and risk factors for ADR-related hospital admissions in elderly patients with dementia or cognitive impairment. Funded by: Royal Hobart Hospital Research Foundation - Grant-Incubator ($9,985); University of Tasmania.
  • GRANT
    A fresh look at local practice to prevent blood clots following hip and knee replacement surgery
    1 Jan 2019 - 31 Dec 2019
    People funded by this grant:
    • Mirkazemi C,
    • Peterson G,
    • Bereznicki L,
    • Batt T
    Project Total: $9,791; The project is a retrospective audit of thromboprophylaxis prescribing for hip and knee arthroplasty patients who have undergone (or will undergo) surgery at the RHH between June 2017 and June 2019. Funded by: Royal Hobart Hospital Research Foundation - Grant-Incubator ($9,791); University of Tasmania.
  • GRANT
    Preventing Adverse Drug Reactions in the Elderly
    1 Jan 2019 - 30 Jun 2023
    People funded by this grant:
    • Bereznicki L,
    • Curtain C,
    • Bereznicki B,
    • Cousins J,
    • Connolly M
    Project Total: $274,000; Based on our prospective adverse drug reaction (ADR) registry:1 * 15% of medical admissions to Tasmanian public hospitals in elderly patients were ADR-related, * 89% were preventable, * 17% patients had a repeat ADR within 12 months, and * One third of patients with repeat ADRs experienced the same ADR caused by the same medications. From this clinical registry, we developed and validated an ADR risk prediction score (PADR-EC).2 We hypothesise that ADR risk stratification during hospitalisation and communication of this risk, together with recommendations that target the specific risk factors identified, to GPs at discharge will reduce the risk of ADR-related hospitalisation. Design: A randomised controlled trial (RCT) at the Royal Hobart Hospital, the major public hospital in Tasmania. Population: Over 12-months, 1000 patients ≥65 years with unplanned admissions to medical wards will be recruited and randomly allocated to intervention or control groups. Intervention: A researcher will perform an ADR risk assessment using the PADR-EC Score,2 which is the sum of points assigned to 5 independent predictors of ADR-related hospitalisation. Based on the PADR-EC Score and the specific risk factors identified, recommendations to reduce the risk of ADRs will be determined. Recommendations will relate to: * post-discharge medication management services, * monitoring of specific parameters/medications, and * de-prescribing strategies. The PADR-EC Score and recommendations will be communicated to the patient and clinical team during hospitalisation, and the patient's GP, alongside the usual information, in the electronic discharge summary. Control: Usual hospital care, with GPs receiving the standard discharge summary. Follow up: All participants will be followed by the research team for 12-months to identify ADRs (including their management and outcome) and health services received. Outcomes: ADR-related hospitalisation (primary); ADRs requiring hospital treatment, change in therapy or specific treatment (secondary). The study will be powered to detect a 5% difference in the primary outcome Funded by: Hospitals Contribution Fund Research Foundation - HCF - Grant-Health Services Research Program ($274,000); University of Tasmania.
  • GRANT
    ReMInDAR Trial Reducing Medicine Induced Deterioration and Adverse Reactions Trial
    1 May 2018 - 31 Mar 2021
    People funded by this grant:
    • Bereznicki L,
    • Roughead L,
    • Pratt N,
    • Parfitt G,
    • Cousins J
    Project Total: $2,847,927; This randomised controlled trial will assess a pharmacist led intervention to reduce medicine induced deterioration and adverse reactions. Medicine induced deterioration encompasses the spectrum of side effects that are frequently not recognised as medication related but are misattributed as geriatric syndromes, frailty or changes due to aging?. The aim of the service is to enable early identification of signs and symptoms of medicine- induced deterioration so that worsening frailty and subsequent adverse events, such as injurious falls, fractures and delirium are prevented. In implementing the service, the pharmacist will use a suite of validated tools to assist in the detection of signs and symptoms of medicine-induced deterioration. The validated tools will encompass assessments to monitor changes in cognition, change in 24-hour movement behavior, including sleep, as well as grip strength. In addition, pharmacists will assess the potential for adverse medicine events via review of the resident care assessment record and through patient or carer reported changes in health since the medicine regimen was changed. The pharmacist service will be compared with usual care. The trial, involving 500 patients will take place in aged-care facilities in South Australia and Tasmania. Evaluation will encompass health program, clinical and economic evaluation. The expected clinical outcome is a reduction in medication-induced deterioration, as measured by change in frailty score. Adverse events will be measured as a secondary outcome. The cost- effectiveness evaluation will assess cost per adverse event avoided. Funded by: Department of Health, Disability and Ageing (Cth) - Pharmacy Trial Program (Tranche 2) ($2,847,927); University of Tasmania.
  • GRANT
    'What's your beat?': Reducing strokes through AF awareness and screening
    1 Jan 2018 - 30 Apr 2019
    People funded by this grant:
    • Peterson G,
    • Wimmer B,
    • Bereznicki L,
    • Macintyre K,
    • Khanam M
    Project Total: $69,182; Stroke continues to be a major public health issue. It is the third most common cause of death. The financial cost in Australia is estimated to be $5 billion each year. Tasmania and South Australia are the worst affected States. Atrial fibrillation (AF), the most common sustained cardiac arrhythmia, is a major modifiable risk factor for stroke. AF is associated with a five times increased risk of stroke and is responsible for up to 25% of strokes in elderly adults. Recently, international guidelines and expert consensus statements have recommended more widespread screening for AF in those aged 65 years or older. The case is compelling - AF is common and a leading cause of stroke. Unfortunately, AF often has no symptoms and is commonly undiagnosed or untreated by the time stroke occurs. AF-related strokes are associated with significant morbidity, mortality, and healthcare costs, yet they are highly preventable with the use of warfarin or newer anticoagulant drugs. Given the availability of effective therapy, along with accurate and inexpensive screening technology, population-based AF screening has the potential to become an important public health program. In older age groups, identification and management of AF is the most significant way to prevent stroke. Internationally, there have been recent recommendations for more widespread screening for AF in those aged 65 years or older, as a cost-effective strategy for stroke prevention. This project will raise public awareness of AF and improve its detection, and subsequently lessen the burden of stroke in Tasmania. We intend to screen approximately 3,000 Tasmanians aged 65 years or older, and without previously diagnosed AF. Screening will take place throughout most of 2018 at a range of community venues across Tasmania. Funded by: Tasmanian Community Fund - Grant ($69,182); University of Tasmania ($9,000).
  • GRANT
    Getting Asthma Under Control
    3 Nov 2017 - 30 Jun 2020
    People funded by this grant:
    • Armour C,
    • Krass I,
    • Bosnic-Anticevich S,
    • Saini B,
    • Bereznicki L
    Project Total: $2,074,100; We will conduct a cluster randomised trial, with asthma control being the main inclusion criterion and clinical outcome measured. The three study arms are: Group A (Pharmacy Asthma Service): eligible patients will receive four private consultations with the pharmacist, at baseline, one month, six months (via telephone) and 12 months. The consultations will focus on addressing three key factors associated with uncontrolled asthma: suboptimal adherence characterised by underuse of preventer medication and/or overuse of reliever medication; suboptimal inhaler technique; and/or uncontrolled allergic rhinitis. At each visit, asthma control and a number of secondary outcomes will be assessed. Group B (Low intervention and referral): Patients identified with uncontrolled asthma by the pharmacist will be referred to their general practitioner. Clinical outcomes will be assessed at one month and 12 months. Group C (Usual Care): The third group will be recruited from a comparable sample of patients with asthma, matched by age, gender and asthma control scores from general practice medical records. Asthma control and secondary outcomes for this group will be assessed by the project group at baseline and 12 months. Funded by: Department of Health, Disability and Ageing (Cth) - Pharmacy Trial Program (Tranche 2); Woolcock Institute of Medical Research; University of Tasmania.
  • GRANT
    Does hospital opioid prescribing increase the risk of chronic opioid use?
    1 Jan 2017 - 31 Jan 2018
    People funded by this grant:
    • Veal F,
    • Bereznicki L,
    • Thompson A,
    • Orlikowski C,
    • Boyles P
    Project Total: $9,233; Chronic opioid use for persistent pain is skyrocketing and is associated with substantial patient harm. This study will review what the risk of chronic opioid use is following a supply of an opioid at discharge from the Royal Hobart Hospital and make recommendations to improve the way opioids are prescribed. Funded by: Royal Hobart Hospital Research Foundation - Grant-Starter ($9,233); University of Tasmania.
  • GRANT
    Investigating the burden of childhood fever on Tasmanian families and the Royal Hobart Hospitals Emergency Department.
    1 Jan 2016 - 31 Dec 2016
    People funded by this grant:
    • Bereznicki B,
    • Beggs S,
    • Bereznicki L,
    • Zosky G
    Project Total: $9,599; This project will describe the presentations to the Royal Hobart Hospital emergency department by children with fever, investigate the knowledge, beliefs and perceptions about childhood fever among parents and caregivers in Tasmania, and develop an educational package for parents and caregivers about childhood fever. Funded by: Royal Hobart Hospital Research Foundation - Grant-Starter ($9,599); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Medicines Australia Continuing Education Program
    1 Jan 2016 - 31 Dec 2024
    People funded by this grant:
    • Peterson G,
    • Bereznicki L,
    • Dwan C,
    • Ling T,
    • Bindoff I
    Project Total: $1,200,000; The project is designed to educate medical representatives from pharmaceutical companies to a recognised industry standard and is a compulsory requirement for all professionals working in this area. The contract also contains specific research objectives. Funded by: Medicines Australia ($1,200,000); University of Tasmania.
  • GRANT
    Development of a decision support smartphone app to improve antithrombotic prescribing in atrial fibrillation
    1 Mar 2015 - 28 Feb 2016
    People funded by this grant:
    • Chalmers L,
    • Bereznicki L,
    • Prasard R,
    • Hancock N,
    • MacIntyre P
    Project Total: $12,000; The objectives of this study are to: * Develop and validate a decision support smartphone application ('app') to support prescribers in the choice of thromboprophylaxis in patients with atrial fibrillation (AF), * Evaluate the effect of the tool on prescriber confidence in choosing antithrombotic agents for patients with AF based on patient age, comorbidities, concomitant drug therapy and other characteristics, and * Evaluate the effect of the tool on the prescribing patterns of antithrombotic therapy in patients admitted to the RHH with AF. Funded by: Royal Hobart Hospital Research Foundation - Grant-Clinical Research ($12,000); University of Tasmania.
  • GRANT
    Games for Health: A technology platform for health and wellbeing (G4HEALTH)
    1 Jan 2015 - 31 Dec 2017
    People funded by this grant:
    • Smith S,
    • Peterson G,
    • Bereznicki L,
    • Loo S,
    • Maxwell-Stewart H
    Project Total: $250,000; G4HEALTH will develop a digital game platform that will enable University of Tasmania researchers, in collaboration with industry partners, to provide a benefit for the community, and place the University at the forefront of the billion dollar games for health industry. Platform and game development will involve a cross-disciplinary community of researchers with expertise from engineering, science, education, and health through to arts. It will consist of off-the-shelf sensors and devices capable of measuring physical activity, providing feedback, delivering narrative-driven games to encourage activity, and transmitting the resulting data. Technologies identified and games and story developed will be used in two proposed intervention studies to increase engagement in physical activity by older adults, people living with chronic disease and adults in a workplace setting in the North of Tasmania. The project will position the University of Tasmania at the forefront of National activities in the Games for Health space and is aligned with the Tamar Health concept. Funded by: University of Tasmania - Grant-Strategic Research; University of Tasmania ($250,000).
  • CONSULTANCY/CONTRACT RESEARCH
    Pharmacy Oral Examination: Examiner Training Development
    1 Jan 2015 - 31 Dec 2015
    People funded by this grant:
    • Bereznicki L,
    • Chalmers L,
    • Rasiah R,
    • Cooper J
    Project Total: $14,033; This project will ensure that resources and training are provided for examiners to produce a reliable and consistent training process that will ensure candidates are reliably assessed on their ability to demonstrate that they can work safely, professionally and ethically unsupervised. Funded by: University of Newcastle ($14,033); University of Tasmania.
  • GRANT
    Impact of community pharmacy services on screening for chronic kidney disease
    1 Aug 2014 - 31 Oct 2016
    People funded by this grant:
    • Castelino R,
    • Peterson G,
    • Bereznicki L,
    • Razi Zaidi T,
    • Jose M
    Project Total: $26,775; This project aims to investigate if community pharmacy screening and intervention helps improve the management of kidney disease, which has been increasing steadily in Tasmania. Funded by: Tasmanian Community Fund - Grant ($26,775); University of Tasmania.
  • GRANT
    Management of post-operative pain and the progression to persistent post-operative pain
    26 Sep 2013 - 30 Apr 2015
    People funded by this grant:
    • Orlikowski C,
    • Bereznicki L,
    • Peterson G,
    • Thompson A,
    • Veal F
    Project Total: $8,634; This project is a prospective, cross sectional study designed to ascertain patient or management factors that increase the risk of developing PPP, with the objective of designing a predictive model to identify high risk PPP candidates. PPP will be defined as pain at the surgical site 3 months after surgery, with severe pain being defined as 5 or more on a 10-point scale. The project involves recruitment of patients, surveys, medical chart data collection, inclusion criteria, exclusion criteria, sample size, data analysis, and assessment of variables. Funded by: Royal Hobart Hospital Research Foundation - Grant-Starter ($8,634); University of Tasmania.
  • GRANT
    Educating Tasmanians about anticoagulant medications
    4 Sep 2013 - 30 Jun 2014
    People funded by this grant:
    • Bereznicki L,
    • Chalmers L,
    • Peterson G,
    • van Tienen E
    Project Total: $10,435; Atrial fibrillation (AF) is a common heart arrhythmia, which affects approximately 2% of all Australians, and almost 10% of people over the age of 75 years. AF is associated with a 5-fold increase in the risk of stroke. Anticoagulant therapies like warfarin, dabigatran, rivaroxaban and apixaban are highly effective in reducing the risk of stroke associated with AF, but also place patients at risk of bleeding adverse events. It is therefore critical that anticoagulant therapies are used appropriately in people with AF, to ensure that the right patients receive them and that the risk of bleeding is kept as low as possible. This project will enable Tasmanians taking anticoagulant therapy access to high quality, independent educational resources focussed on improving the use of this commonly used but high-risk group of medications. The project is focussed on developing educational resources for people taking the commonly used anticoagulant drug warfarin, and three new anticoagulant medications (dabigatran, rivaroxaban and apixaban). These medicines are used to prevent stroke in people with atrial fibrillation, as well as prevent and treat deep vein thrombosis and pulmonary embolism. Given the demographics of Tasmania's community, the use of these medicines and need for relevant educational support of consumers is highest in this State. The project will develop educational tools for consumers and health professionals, and promote these resources to general practices and community pharmacies. Funded by: Tasmanian Community Fund - Grant ($10,435); University of Tasmania.
  • GRANT
    Outcomes of antithrombotic therapy in a new era: the Tasmanian experience
    1 Jul 2012 - 31 Dec 2013
    People funded by this grant:
    • Chalmers L,
    • Bereznicki L,
    • Peterson G,
    • Hancock N,
    • Roberts-Thomson P
    Project Total: $12,545; Funded by: Royal Hobart Hospital Research Foundation - Grant-Research ($12,545); University of Tasmania.
  • GRANT
    Adverse Drug Reactions as a Cause of Hospital Admission in the Elderly
    1 Jan 2012 - 31 Dec 2012
    People funded by this grant:
    • Bereznicki L,
    • Chalmers L,
    • Jose M
    Project Total: $13,000; Funded by: University of Tasmania - Grant-Research Enhancement (REGS); University of Tasmania ($13,000).
  • GRANT
    Fucoidan and marine polyphloroglucinols
    1 Jan 2012 - 31 Mar 2015
    People funded by this grant:
    • Peterson G,
    • Patel R,
    • Bereznicki L
    Project Total: $85,000; Brown algal extracts, in particular those containing fucoidan and marine polyphloroglucinols, have been shown to have potential applications in a number of health indications such as pre-diabetes, immunomodulation, cardiovascular disease and inflammation. With advances in technology, fucoidan and marine polyphloroglucinol extracts from brown seaweed can now be produced successfully on a commercial scale. These types of extracts are beginning to become more prevalent as ingredients in western dietary supplement markets. However, for the extracts to successfully enter this market, efficacy, safety and provenance must be proven. With this in mind, the objectives of this PhD project include the following: to establish a generic analytical method that can be used to fingerprint and quantify fucoidan concentrations in solution, serum and urine; to determine the ability of a commercially available fucoidan/polyphloroglucinol extract (Maritech Synergy) to inhibit the uptake of glucose via an acute human study; to assess the effects of Maritech Synergy on health indications including glucose control, insulin sensitivity and pre-diabetes in a human setting; and to further the understanding of fucoidan and its metabolism. Funded by: Marinova Pty Ltd - Clinical Trial ($85,000); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Warfarin Booklet Rewrite
    1 Jan 2012 - 31 Dec 2012
    People funded by this grant:
    • Peterson G,
    • Bereznicki L,
    • Chalmers L
    Project Total: $1,680; Funded by: Aspen Pharmacare Australia ($1,680); University of Tasmania.
  • GRANT
    Evidence to Practice Gap: Factors that Influence Practices to Prevent Blood Clots Following Hip and Knee Replacement Surgery
    11 Apr 2011 - 11 Apr 2012
    People funded by this grant:
    • Peterson G,
    • Bereznicki L,
    • Hansen E,
    • Mirkazemi C
    Project Total: $4,545; Funded by: Royal Hobart Hospital Research Foundation - Grant-Starter ($4,545); University of Tasmania.
  • GRANT
    Factors Influencing the Outcomes of Therapy with the Anti-clotting medication, Clopidogrel, in Patients with Acute Coronary Syndromes
    11 Apr 2011 - 11 Apr 2012
    People funded by this grant:
    • Peterson G,
    • Bereznicki L,
    • Vonna A,
    • Chalmers L,
    • van Tienen E
    Project Total: $4,545; Funded by: Royal Hobart Hospital Research Foundation - Grant-Starter ($4,545); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    A Review of the Management of Childhood Asthma in Tasmania
    1 Jan 2011 - 31 Dec 2011
    People funded by this grant:
    • Bereznicki B,
    • Bereznicki L
    Project Total: $5,500; Funded by: Asthma Foundation of Tasmania ($5,500); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Clinical Interventions in Pharmacy Online Training Materials
    1 Jan 2011 - 31 Dec 2011
    People funded by this grant:
    • Peterson G,
    • Bereznicki L
    Project Total: $10,000; Funded by: Pharmaceutical Society of Australia ($10,000); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Clinical Interventions Workshop
    1 Jan 2011 - 31 Dec 2011
    People funded by this grant:
    • Peterson G,
    • Bereznicki L,
    • Thompson A
    Project Total: $49,075; Funded by: Pharmaceutical Society of Australia ($49,075); University of Tasmania.